苯二氮䓬类药物或抗组胺药治疗急性眩晕的疗效:系统评价与Meta分析
该系统评价与Meta分析检索多个数据库至2019年1月14日,纳入27项随机临床试验,其中17项(共1586例参与者)进入定量Meta分析。7项试验(802例)评估主要结局,显示单剂抗组胺药在2小时100分制眩晕视觉模拟量表(VAS)评分改善上显著优于苯二氮䓬类药物(差值16.1,95%CI 7.2至25.0),但与其它活性对照药相比无显著差异(差值2.7,95%CI -6.1至11.5)。1周和1个月时,每日苯二氮䓬类或抗组胺药均未报告优于安慰剂。中等强度证据提示单剂抗组胺药在2小时缓解眩晕方面优于单剂苯二氮䓬类,现有证据不支持苯二氮䓬类药物与急性眩晕任何结局改善相关。
要点
- 单剂抗组胺药在2小时100分制眩晕VAS评分改善上显著优于单剂苯二氮䓬类(差值16.1)。
- 单剂抗组胺药与其它活性对照药在2小时眩晕VAS评分改善上无显著差异。
- 1周和1个月时,每日苯二氮䓬类或抗组胺药均未报告优于安慰剂。
核心结论
- 中等强度证据提示单剂抗组胺药在2小时缓解眩晕方面优于单剂苯二氮䓬类。
- 现有证据不支持苯二氮䓬类药物与急性眩晕任何结局改善相关。
- 其它证据提示每日使用抗组胺药可能对急性眩晕患者无益。
- 需要更大规模的随机试验比较抗组胺药和苯二氮䓬类与安慰剂,以更好阐明这些药物的相对疗效。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、CENTRAL、EMBASE、CINAHL、Scopus和ClinicalTrials.gov数据库自建库至2019年1月14日,无语言限制,并筛选纳入研究的参考文献和相关综述。
- 纳入随机临床试验(RCT),比较抗组胺药或苯二氮䓬类与另一对照、安慰剂或无干预,用于急性眩晕持续时间2周或更短的患者。
- 排除健康志愿者、预防性治疗或诱发性眩晕的研究,以及比较同一类别两种药物的研究。
- 系统评价共纳入27项试验,其中17项进入定量Meta分析,共1586例参与者。
- 7项试验共802例参与者评估主要结局。
主要发现
- 单剂抗组胺药在2小时100分制眩晕或头晕VAS评分改善上显著优于苯二氮䓬类(差值16.1,95%CI 7.2至25.0)。
- 单剂抗组胺药与其它活性对照药在2小时100分制眩晕或头晕VAS评分改善上无显著差异(差值2.7,95%CI -6.1至11.5)。
- 在1周和1个月时,每日苯二氮䓬类或抗组胺药均未报告优于安慰剂。
- 评估单剂后2小时即刻效应的RCT偏倚风险普遍较低,而评估1周和1个月结局的RCT偏倚风险高。
关键数值与推荐
- 主要结局为治疗后2小时10分制或100分制眩晕或头晕VAS评分变化。
- 次要结局包括2小时恶心VAS评分变化、2小时补救药物使用、1周或1个月眩晕改善或缓解。
临床怎么用
- 中等强度证据提示单剂抗组胺药在2小时缓解眩晕方面优于单剂苯二氮䓬类。
- 现有证据不支持苯二氮䓬类药物与急性眩晕任何结局改善相关。
- 其它证据提示每日使用抗组胺药可能对急性眩晕患者无益。
- 作者认为需要更大规模的随机试验比较抗组胺药和苯二氮䓬类与安慰剂,以更好阐明这些药物的相对疗效。
局限性
- 评估1周和1个月结局的随机对照试验具有高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute vertigo can be disabling. Antihistamines and benzodiazepines are frequently prescribed as "vestibular suppressants," but their efficacy is unclear. OBJECTIVE: To assess the efficacy of antihistamines and benzodiazepines in the treatment of acute vertigo from any underlying cause. DATA SOURCES: We searched the PubMed, CENTRAL, EMBASE, CINAHL, Scopus, and ClinicalTrials.gov databases from inception to January 14, 2019, without language restrictions. Bibliographies of the included studies and relevant reviews were also screened. STUDY SELECTION: We included randomized clinical trials (RCTs) comparing antihistamine or benzodiazepine use with another comparator, placebo, or no intervention for patients with a duration of acute vertigo for 2 weeks or less. Studies of healthy volunteers, prophylactic treatment, or induced vertigo were excluded, as were studies that compared 2 medications from the same class. DATA EXTRACTION AND SYNTHESIS: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, data were extracted and risk of bias was assessed by 2 authors independently for each study. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: The predefined primary outcome was change in 10- or 100-point vertigo or dizziness visual analog scale (VAS) scores at 2 hours after treatment. Secondary outcomes included change in nausea VAS scores at 2 hours, use of rescue medication at 2 hours, and improvement or resolution of vertigo at 1 week or 1 month. RESULTS: Of the 27 trials identified in the systematic review, 17 contributed to the quantitative meta-analysis and involved a total of 1586 participants. Seven trials with a total of 802 participants evaluated the primary outcome of interest: single-dose antihistamines resulted in significantly more improvement on 100-point VAS scores compared with benzodiazepines (difference, 16.1 [95% CI, 7.2 to 25.0]) but not compared with other active comparators (difference, 2.7 [95% CI, -6.1 to 11.5]). At 1 week and 1 month, neither daily benzodiazepines nor antihistamines were reported to be superior to placebo. RCTs comparing the immediate effects of medications (at 2 hours) after a single dose generally had a low risk of bias, but those evaluating 1-week and 1-month outcomes had a high risk of bias. CONCLUSIONS AND RELEVANCE: Moderately strong evidence suggests that single-dose antihistamines provide greater vertigo relief at 2 hours than single-dose benzodiazepines. Furthermore, the available evidence did not support an association of benzodiazepine use with improvement in any outcomes for acute vertigo. Other evidence suggested that daily antihistamine use may not benefit patients with acute vertigo. Larger randomized trials comparing both antihistamines and benzodiazepines with placebo could better clarify the relative efficacy of these medications.
引用
- Hunter BR, Wang AZ, Bucca AW, et al. Efficacy of Benzodiazepines or Antihistamines for Patients With Acute Vertigo: A Systematic Review and Meta-analysis. JAMA Neurol. 2022. PMID: 35849408. doi:10.1001/jamaneurol.2022.1858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。